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Takotsubo syndrome (TTS) is an acute cardiac syndrome characterized by regional left
ventricular dysfunction with a peculiar circumferential pattern, which typically results
in apical ballooning. Evidence indicates a pivotal role of catecholamines in TTS, and
researchers have discussed multiple hypotheses on the etiology, including multivessel
coronary spasm, myocardial stunning, excessive transient ventricular afterload, and
cardiac sympathetic overactivity with local noradrenaline spillover. Although central
nervous system disorders, such as stroke and epilepsy, are known to trigger TTS,
the incidence and clinical features of TTS in neurodegenerative disorders are poorly
understood. Here, we retrospectively examined TTS cases in a single-center cohort
composed of 250 patients with amyotrophic lateral sclerosis (ALS) and 870 patients
with synucleinopathies [582 patients with Parkinson’s disease (PD), 125 patients with
dementia with Lewy bodies (DLB), and 163 patients with multiple system atrophy
(MSA)] and identified 4 (1.6%, including 2 women) cases with ALS and no cases with
synucleinopathies. Two ALS patients underwent autopsy and the pathological findings
were compatible with the chronological changes identified in catecholamine-induced
cardiomyopathy. A literature review identified 16 TTS cases with ALS, 1 case each with
PD and DLB, and no cases with MSA. When current and previous TTS cases with ALS
were concatenated: 55% (11/20) were female; 35% (7/20) had a bulbar-onset and 45%
(9/20) had a limb-onset; the mean age of TTS onset was 63.3 ± 9.0 years and the mean
interval time from ALS onset to TTS development was 4.9± 3.0 years; no (0/16) patients
developed TTS within 12 months after ALS onset; 50% (10/20) underwent artificial
ventilations; the mortality was 17% (3/18); and most cases had precipitating factors, and
TTS development was associated with gastrostomy, tracheostomy, or infections in 45%
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(9/20) of the patients. This study demonstrated that ALS is a considerable predisposing
factor of TTS and that synucleinopathies rarely cause TTS. The distinct TTS incidence
between ALS and synucleinopathies may be due to cardiac sympathetic overactivity in
ALS and may also be affected by cardiac sympathetic denervation in synucleinopathies.
Moreover, the etiology of TTS in ALS may be reasonably explained by the two-hit theory.
Keywords: takotsubo syndrome, amyotrophic lateral sclerosis, synucleinopathy, Parkinson’s disease, dementia
with Lewy bodies, multiple system atrophy, sympathetic nerve, noradrenaline
INTRODUCTION
Takotsubo syndrome (TTS) is an acute cardiac syndrome
characterized by regional left ventricular dysfunction with a
peculiar circumferential pattern, which typically results in apical
ballooning of the left ventricle at end systole. The abnormality
extends beyond the coronary artery supply regions, which
distinguishes TTS from acute coronary syndrome. A wide variety
of emotional and physical stress, including anger, shock, and
illness, triggers TTS, and female sex is a strong predisposing
factor for TTS development (1, 2).
Multiple lines of evidence have demonstrated the pivotal role
of catecholamines in developing TTS (3–8), and researchers
have proposed and discussed various hypotheses on the etiology,
including multivessel coronary spasm, myocardial stunning, and
excessive transient ventricular afterload (1). A recent review
also suggested that cardiac sympathetic overactivity and local
noradrenaline spillover may be fundamental in the etiology (9).
Central nervous system (CNS) disorders may cause TTS, and
stroke and epilepsy are the most frequent causes among these
disorders. In a review of TTS in CNS disorders, most TTS
cases developed with acute-onset or paroxysmal CNS disorders
(3). A unique exception is amyotrophic lateral sclerosis (ALS),
which is a neurodegenerative disorder characterized by chronic,
progressive upper and lower motor neuron death. The intriguing
link between ALS and TTS may be explained by the increased
cardiac noradrenergic activities that ALS patients continuously
endure (10, 11). In contrast, synucleinopathies, including
Parkinson’s disease (PD), dementia with Lewy bodies (DLB), and
multiple system atrophy (MSA), have rarely been reported to
cause TTS (3), although they are also physically and mentally
disabling and substantially more prevalent neurodegenerative
disorders. The precise reason is unknown; however, it may be due
to underreporting and no cohort study has investigated the TTS
incidence in neurodegenerative disorders, with the exception of
ALS.
The aim of this study is to retrospectively identify patients
complicated by TTS in our cohort of ALS and synucleinopathies
and assess the difference in the TTS incidence between these two
entities. We also performed a literature review that focused on
TTS cases accompanied by ALS or synucleinopathies.
MATERIALS AND METHODS
Subjects
This study was approved by the Ethics Committee of the
Tokushima University Hospital and written informed consent
was obtained from the participant for the publication of this
case report. We identified cases using medical records at
the Tokushima University Hospital between June 2006 and
December 2017, which included 250 patients with ALS and 870
patients with synucleinopathies (PD, 582; DLB, 125; MSA, 163).
The latest patient accrual was September 2016. The diagnosis
of ALS, PD, DLB, and MSA was made based on the revised El
Escorial criteria (12), UK Brain Bank criteria (13), third report of
the DLB Consortium (14), and second consensus statement on
the diagnosis of MSA (15), respectively. TTS was diagnosed on
the basis of the International Takotsubo Diagnostic Criteria (2).
Statistical Analysis
Differences in the incidence of TTS between ALS and
synucleinopathies were tested for significance using Fisher’s
exact test and the Haldane–Anscombe correction was used for
calculating the odds ratio. The test was 2-sided and the limit for
statistical significance (P) was set at 0.05. Statistical analysis was
performed using R version 3.5.1. (R Foundation for Statistical
Computing, Vienna, Austria) Data is presented as mean ±
standard deviation, unless stated otherwise.
Literature Review
A review of the literature was conducted to identify published
cases of TTS with ALS or synucleinopathies (PD, DLB,
and MSA). We searched PubMed and Google Scholar to
identify relevant articles using the following MeSH terms:
ALS, motor neuron disease, Parkinson disease, Parkinson’s
disease, Lewy body disease, dementia with Lewy bodies, multiple
system atrophy, olivopontocerebellar atrophy, striatonigral
degeneration, Shy-Drager syndrome, takotsubo cardiomyopathy,
tako-tsubo cardiomyopathy, takotsubo syndrome, and tako-
tsubo syndrome. We also manually examined the reference lists
in relevant articles.
RESULTS
Four (1.6%, 4 of 250) patients with ALS developed TTS
during the evaluation period, whereas no patients with
synucleinopathies developed TTS. The incidence of TTS was
significantly higher in the patients with ALS than in those with
synucleinopathies (odds ratio 31.78, and 95% confidence interval
1.71–592.38, P = 0.002). Of the 4 ALS patients with TTS, 2
patients were women, and the mean age at TTS onset was 65.8
± 9.6 (range, 55–78) years. The mean interval time between
ALS onset and TTS development was 5.8 ± 3.4 (range, 2.8–10)
years. Two patients underwent tracheostomy-invasive ventilation
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(TIV). Only 1 patient reported chest pain and 3 patients were
complicated by acute infections. One patient died acutely after
the development of TTS.
Case Report
Case 1
A 71-year-old woman presented with a chief complaint of
dysarthria and was subsequently diagnosed with ALS. At age
75, her breathing became difficult, and she underwent TIV. At
age 78, she was hospitalized due to fever, tachycardia, hypoxia,
and drowsiness. She had pyuria and increased white blood cells
and C-reactive protein. An ECG showed ST elevation in V1–
V5. Echocardiography demonstrated markedly decreased wall
motion in the apex, which was incongruent with the coronary
artery supply region. The basal motion was normal. She was
diagnosed with a urinary tract infection and TTS. Eleven days
after admission, the abnormal wall motion and her symptoms
completely disappeared.
Case 2
A 57-year-old man presented with right arm weakness and
was diagnosed with ALS. At age 60, he underwent TIV
due to progressive dyspnea. At age 67, he was admitted to
our hospital due to respiratory discomfort. An ECG showed
negative T waves in V1-V6, and echocardiography indicated
decreased wall motion over the entire circumference of the
apical region. Blood testing showed increased white blood cells,
transaminase, gamma-glutamyl transpeptidase, and C-reactive
protein. Abdominal CT demonstrated wall thickening of the
common bile duct, which was consistent with acute cholangitis.
The cholangitis was successfully treated with antibiotics. The wall
motion abnormality and his symptoms completely disappeared,
and he was discharged from our hospital after 27 days.
Case 3
A 60-year-old man presented with weakness in the left
foot. He subsequently developed dysarthria and swallowing
difficulties and was diagnosed with ALS. At age 63, he was
admitted to our hospital with fever and exacerbation of
swallowing difficulties, and he was diagnosed with aspiration
pneumonia. Two days after admission, he reported chest
pain. An ECG indicated negative T waves in V3–V6. An
echocardiogram indicated severe left ventricular dysfunction
with akinesia; however, the basal segments were preserved
(Figures 1A,B, Supplementary Video 1). The ejection fraction
was 20%. Coronary angiography did not indicate any significant
stenosis. Although his chest pain subsided with conservative
treatment, he underwent tracheostomy due to difficulties
in sputum expectoration. The abnormal wall motion was
subsequently resolved (Figures 1C,D, Supplementary Video 2).
He was transferred to another hospital and died at 65 years
of age. Pathological examination of the heart demonstrated no
coronary stenosis (Figures 2A–C) and localized patchy fibrosis
that occurred toward the endocardium of the left anterior wall
(Figures 2D,E). The neuropathological findings were consistent
with ALS [Brettschneider stage 4 (16) and Nishihira Type 2 (17)]
(Figures 3A–D).
Case 4
A 52-year-old woman presented with dysarthria, followed by
swallowing difficulties and limb weakness, and she was diagnosed
with ALS. At age 55, she developed hypoxia and consciousness
disturbance after excreting a large amount of stool induced
by an enema. An ECG indicated abnormal Q wave in V3
and ST elevation in V2–V3. Echocardiogram revealed diffuse
akinesia in the apex with preserved wall motion in the basal
segments. She died of hypoxia on the following day. Pathological
examination of the heart demonstrated no apparent occlusion
of the coronary artery (Figures 2F–H). Patchy myocardial
necrosis was observed in the anterior wall of the apex and
the intraventricular septum, accompanied by inflammatory cell
infiltration that mainly involved neutrophils and lymphocytes
(Figures 2I,J). Intraventricular hemorrhage was also observed.
The neuropathological findings were consistent with ALS
(Brettschneider stage 4 and Nishihira Type 1) (Figures 3E–H).
Literature Review
We identified 8 reports that addressed ALS patients complicated
with TTS and 1 report each for PD and DLB with TTS, including
16 TTS cases for ALS and 1 case each for PD and DLB (10, 18–
26). Table 1 shows a summary of 20 cases of ALS complicated
with TTS, including 4 cases from this study. Of these 20 cases,
9 (45%) cases were male and 11 (55%) cases were female. The
onset types of ALS were bulbar in 7 (35%) cases, cervical in 7
(35%) cases, lumbar in 2 (10%) cases, dyspnea in 1 (5%) case,
and not clearly indicated in 3 (15%) cases. The mean age of
TTS onset was 63.3 ± 9.0 (range, 40–75) years, and the mean
interval time from ALS onset to TTS development was 4.9 ±
3.0 (1.5–11.2) years. Ten (50%) patients underwent TIV or non-
invasive ventilation (NIV). The predisposing or precipitating
factors of TTS varied; however, TTS development was associated
with surgery or interventional endoscopy in 5 (25%) patients.
Four (20%) cases, including 3 of our cases, were complicated
by various acute infections. Among 18 patients whose prognoses
were documented, 3 (17%, including 2 women) patients died of
TTS.
A reported case with PD developed TTS after initiating
entacapone, a cardiac catechol-O-methyltransferase (c-COMT)
inhibitor (18). The authors suggested a potential relationship
between TTS and entacapone intake as the inhibition of c-COMT
activity with entacapone increases noradrenaline, adrenaline,
and dopamine bioavailability. The case with DLB, who showed
decreased cardiac (123I) metaiodobenzyl guanidine (MIBG)
uptake, developed TTS without chest pain (19). With the
exception of depression, the apparent precipitating factors were
not described in the report.
DISCUSSION
TTS in ALS
Regarding the incidence of TTS in ALS, Choi et al. investigated 64
of 624 ALS patients who exhibited chest symptoms and identified
9 (1.4% of overall patients and 14.1% of patients with positive
chest symptoms) patients with TTS (10). The incidence rate
was close to that of our current study (1.6%). Here, we further
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FIGURE 1 | Apical 4-chamber views of transthoracic echocardiography of Case 3. (A,B) The broad anterior wall including apex (arrowheads) showed akinesis at the
onset. (C,D) Myocardium of the region became hypertrophied and showed normal wall motion 2 weeks after the onset.
confirmed that ALS is a substantial risk for developing TTS,
considering only 0.02% of all hospitalizations in the United States
(n= 33,506,402) were diagnosed with TTS (27).
TTS is associated with catecholamine excess (3), and exposure
to catecholamines and beta-receptor agonists precipitates all
features of TTS in humans (4). Biopsy samples from TTS
patients demonstrated morphological changes compatible with
catecholamine-induced myocardial damage (5–7), and the apical
myocardium of the left ventricle has a high density of β-
adrenoceptors, being particularly sensitive to catecholamines
(8). Moreover, evidence has demonstrated impaired autonomic
nervous systems in ALS patients. Patients in the early stage of
ALS may have a higher resting heart rate and blood pressure
and an increased plasma noradrenaline level, which indicate
an increased sympathetic tone (28, 29). In the advanced stage
requiring artificial ventilations, hypertensive crisis may occur
(30). These findings indicate that the high incidence of TTS in
ALS is due to sympathetic overactivity.
A recent review indicated that cardiac sympathetic
overactivity and local noradrenaline spillover may be
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FIGURE 2 | Pathological findings of the heart. Case 3: no occlusion was observed in the left anterior descending coronary artery (A), the left circumflex coronary
artery (B), and the right coronary artery (C). Patchy fibrosis was observed in the left anterior wall (D,E). Case 4: no occlusion was observed in the left anterior
descending coronary artery (F), the left circumflex coronary artery (G), and the right coronary artery (H). Myocardial necrosis was observed in the anterior wall of the
apex (H) and the intraventricular septum (J), accompanied by neutrophils and lymphocytes (A–D,F–J) hematoxylin and eosin staining. (E) Azan staining. Bars = 1mm
for (A–C), 500µm for (D–H) and 50µm for (I,J).
fundamental in the etiology of TTS (9). Interestingly, a
model of sudden brain death demonstrated massive increases in
myocardial interstitial noradrenaline levels; however, the serum
catecholamine remained relatively unchanged (31). Similarly,
sympathectomy, but not adrenalectomy, prevented a left
ventricular motion abnormality in baboons after subarachnoid
hemorrhage (32). Importantly, ALS patients show chronic
cardiac sympathetic hyperactivity as evidenced by an increased
washout ratio of cardiac MIBG scintigraphy (11). These
observations may jointly support that local noradrenaline
release associated with cardiac sympathetic overactivity is
more crucial than the systemic catecholamine increase in TTS
development.
Of the 20 patients with ALS complicated with TTS in the
current and previous reports, one half of the patients underwent
TIV or NIV. The use of artificial ventilation is likely to become
physical and psychological burdens in addition to the disease
burden. However, we could not determine whether there is an
additional risk of TTS from this result. The mortality rate was
17%, which was substantially higher than that obtained from a
meta-analysis (4.5%) (33), which likely reflects the diminished
respiratory reserve in ALS. Although a retrospective study of a
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FIGURE 3 | Neuropathological findings of Case 3 and Case 4. Case 3: severe
neuronal loss in the cervical anterior horn (A); phosphorylated TDP-43
immunopositive neuronal cytoplasmic inclusions in the cervical anterior horn
(B); neuronophagia (C), and phosphorylated TDP-43 immunopositive neuronal
and glial cytoplasmic inclusions (D) in the primary motor area. Case 4: severe
neuronal loss in the lumbar anterior horn (E); Bunina body (F, arrowhead) and
phosphorylated TDP-43 immunopositive neuronal cytoplasmic inclusions (G)
in the lumbar anterior horn; neuronophagia (H) in the primary motor area. (A,E)
Klüver-Barrera staining. (B,D,G) Phosphorylated TDP-43 immunostaining.
(C,F) Hematoxylin and eosin staining. (H) CD68 immunostaining. Bars =
200µm for (A,E), 20µm for (B–D,G–H), and 10µm for (F).
large administrative database demonstrated that male patients
with TTS had a higher mortality rate than females (34), among
3 patients who died, 2 were female. Given that none of these 3
patients underwent TIV or NIV, which is occasionally required to
treat acute complications of TTS, we speculate that the decision
whether to use artificial ventilation may be more associated with
mortality than sex in ALS patients.
In contrast to the significant female preponderance in the
general population of TTS (27, 35), the number of female ALS
patients only slightly exceeded that of the male ALS patients. This
finding is partially explained by the gender difference of ALS (the
ratio of affectedmales to affected females is 1.6:1) (36); however, it
may be influenced by unknown factors. The time period between
the ALS onset and development of TTS was documented in
16 patients. Among these patients, 11 patients developed TTS
3 or more years after ALS onset, and no patients developed
TTS within 12 months. This finding suggests that the risk may
increase over time and may relate to the severe autonomic
symptoms observed in an advanced stage (30). Although brain
autonomic dysfunction in ALS potentially contribute to TTS
(29), the number of bulbar-onset patients did not outweigh that
of the limb-onset patients.
Most cases had precipitating factors, and TTS development
was associated with gastrostomy, tracheostomy, or infections in
approximately half of the patients. Interestingly, acute infections
apparently precipitated TTS in 3 of 4 our cases. Although
acute infectious diseases can trigger TTS in some patients
(37), an infection per se is unlikely to cause TTS considering
its prevalence. Therefore, the etiology of TTS in these 3
cases may be best explained by the two-hit theory; acute
infection precipitated TTS under the presence of chronic cardiac
sympathetic overactivity in ALS. This hypothesis seems to fit
clinical presentations in the majority of ALS patients with TTS,
thus illustrating the etiological differences from acute-onset or
paroxysmal CNS disorders, in which the disease per se causes
TTS.
TTS in Synucleinopathies
Synucleinopathies (PD, DLB, and MSA) are common
neurodegenerative diseases characterized by abnormal
accumulation of the aggregates of α-synuclein in neurons,
nerve fibers, or glial cells. Although they are substantially
more prevalent than ALS, our literature review identified
only one case each for PD and DLB accompanied by TTS
(18, 19). More interestingly, there was no report on TTS that
occurred under the presence of MSA, which typically progresses
more rapidly than PD or DLB and is often considered the
most devastating type of synucleinopathy. In contrast to ALS,
autonomic impairments in synucleinopathies present with
constipation, urinary impairments, and orthostatic hypotension,
which typically result from a reduced sympathetic tone. In
PD and DLB, functional impairments of cardiac autonomic
nerves can be visualized by MIBG scintigraphy; most patients
with PD and DLB show significantly decreased cardiac uptake
of MIBG, which reflects postsynaptic cardiac noradrenergic
denervation and is used as an established diagnostic marker
(38). Moreover, ∼30% of patients with MSA exhibit a low MIBG
uptake (39).
Here, we found that no patients with synucleinopathies
developed TTS in our cohort, which is in line with the limited
number of previous reports on synucleinopathies accompanying
TTS. The considerable difference in the TTS incidence between
synucleinopathies and ALSmay solely arise from the sympathetic
overactivity in ALS. Moreover, cardiac sympathetic denervation
in synucleinopathies might widen the incidence gap. To support
this idea, pharmacological and surgical sympathectomies have
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TABLE 1 | Clinical profile of ALS patients with TTS.
Age at TTS
onset
Sex Onset type
of ALS
Duration before
TTS (mo)
Artificial
ventilation
Potential predisposing/
precipitating factors
Cardiac motion
abnormality
Recovery
from TTS
References
60 F Cervical 43 None ND Apical hypokinesia ND (10)
71 M Bulbar 18 NIV PEG installation Mid-apical ballooning with
basal hypercontractility
Partial (10)
57 M Cervical 18 None ND Akinesia at whole apex Full (10)
59 F Cervical 25 None ND Whole mid to apical wall
akinesia
Full (10)
70 F Bulbar 63 NIV † Apical and mid-ventricular
akinesia
Partial (10)
69 F Bulbar 60 TIV ND Apical and mid ventricular
akinesia with hyperdynamic
basal segments
Full (10)
59 M Cervical 69 NIV † Apical akinesia with
ballooning
Full (10)
70 F Cervical 134 TIV † Apico-anterior akinesia Full (10)
55 M Dyspnea ND None Colorectal cancer with
liver metastasis,
Postoperative period
Focal akinesia of mid
inferolateral wall
Full (10)
74 F ND ND None First attack: emotional
stress
Apical ballooning and basal
hyperkinesis
Full (20)
– – – – – Second attack: surgical
stress and hypovolemia
Apical ballooning with
systolic anterior motion of
the mitral valve
Full –
75 F Bulbar ND None Surgical gastrostomy and
hernia repair
Apico-anterior hypokinesia
with hyperdynamic basal
segments
Full (21)
59 F Bulbar 93 TIV ND Apical akinesia with
hyperdynamic basal
segments
Full (22)
63 M Cervical 86 None Aspiration pneumonia and
tracheostomy
Apical hypokinesia with
hyperdynamic basal
segments
Dead (23)
40 M ND 24 NIV ND Typical apical ballooning Full (24)
71 F Lumbar 71 None Difficulty with discharging
sputum
Apical hypokinesia with
hyperdynamic basal
segments
Dead (25)
61 M ND ND NIV ND Apical ballooning ND (26)
78 F Bulbar 85 TIV Urinary tract infection Apical akinesia Full Case 1
67 M Cervical 120 TIV Cholangitis Akinesia at whole apex Full Case 2
63 M Lumbar 34 None Aspiration pneumonia Apico-anterior hypokinesia Full Case 3
55 F Bulbar 38 None Evacuation Diffuse akinesia in the apex Dead Case 4
†
Treated with benzodiazepines, anxiolytics, or tricyclic antidepressants. Ref, reference; ND, not described; NIV, noninvasive ventilation; TIV, tracheostomy-invasive ventilation; PEG,
percutaneous endoscopic gastrostomy.
successfully prevented the induced myocardial changes that
resemble those of TTS in animal models (32, 40). Future clinical
studies that focus on the potential effects of pre-existing cardiac
sympathetic denervation may clarify whether or to what extent
it is protective against the development of TTS in human
diseases.
Pathological Examination
Two patients underwent autopsies (Cases 3 and 4) and
coronary artery occlusion was not observed in these cases,
which further supports the diagnosis of TTS. According
to a histopathological study on 11 TTS cases (6), TTS is
characterized by: (a) an immediate infiltration of inflammatory
cells including neutrophils, followed by (b) the removal of
cardiomyocytes, and then (c) patchy fibrosis. These pathological
features including time-course changes are consistent with
catecholamine-induced cardiomyopathy (7). We observed an
infiltration of neutrophils in Case 4, who died the following
day after TTS, and only patchy focal fibrosis in Case 3, who
underwent an autopsy 2 years after TTS onset. In Case 4,
patchy necrosis and intraventricular hemorrhage were also
observed, which resemble the pathological findings in severe
TTS cases who died acutely after the development of TTS (41,
42).
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Limitations
As this cohort was not originally created to survey sympathetic
function or mental status in neurodegenerative diseases, we did
not perform cardiacMIBG scintigraphy in ALS patients, or assess
the blood catecholamine, anxiety or depression levels. Moreover,
we might have underestimated the incidence of TTS in ALS
and synucleinopathies. ALS patients, particularly patients who
are on artificial ventilations, often have difficulties in reporting
subjective symptoms. Similarly, cardiac sympathetic denervation
in synucleinopathies might mask chest symptoms; sympathetic
autonomic neuropathy has been reported to be associated with
pure silent ischemia (43), and the DLB patient with TTS did not
present chest symptoms (19). Improved recognition of the TTS
risk in ALS as well as possible silent TTS in synucleinopathies
may elucidate a more accurate incidence rate in future studies.
CONCLUSION
This cohort study confirmed that ALS is a considerable
predisposing factor of TTS and demonstrated that
synucleinopathies rarely develop TTS. Our findings also
provide unique opportunities to disentangle the complex
etiology of TTS; local noradrenaline release associated with
cardiac sympathetic overactivity seems to be the most crucial
predisposing factor in ALS, and TTS may not occur until the
“second-hit,” such as when an infection or surgical intervention
occurs. Although the potential effect of pre-existing cardiac
sympathetic denervation has rarely been discussed in the clinical
context, it might affect the development and disease severity of
TTS. Further detailed research on the TTS incidence in different
types of diseases will provide new insights into the etiology of
TTS.
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